Member Info for HighlyGeared

I spoke to the company and they told me. The point being that despite all of the project progression that Jubilee has achieved, they are still deliberately poor at PI shareholder communication and PR. Very frustrating given that the II's had a nice visit from Leon and an update about three weeks ago.

gotreal. There is a recently appointed new CFO.

As a matter of interest, there is a new CFO but JLP forgot to tell PI's.

Give it a rest Homey. With regards to the projects, you know enough to be dangerous. Are you a bean counter?

An example of the difficulties they have had in getting Roan operational with the break down in global supply chains. Leon mentioned they had a processing control unit on order from Ukraine. It disappeared in transit to Zambia. The control unit had to be re-ordered with an 8 month lead time . Jubilee somehow managed to compress that time frame. Just one of the many difficulties in getting a complex project up and running. In my view getting Roan operational within the time frame they have, has been a remarkable achievement.

Libellous rubbish being brought up again. It didn't work last time and it won't this time either. Desperate stuff from desperate individuals.

https://www.biospace.com/article/astrazeneca-rolls-into-aacr-with-60-presentations-new-svo-of-early-oncology/

https://endpts.com/astrazenecas-oncology-rd-chief-susan-galbraith-highlights-their-next-gen-prospects-at-aacr22/

This is being walked up each day on very small volume, which on the surface does not equate. Something must be going on in the background. Holding 10m so hoping for further positive news flow.

https://www.pointbiopharma.com/press-releases/aacr-2022-fap-poster

Marex hoovering up all they can alone on the bid. imo it's the two II shorts covering.

Christina Coughlin
@coughlin582
Excited to join the Board @avacta
The Affimer and preCISION platforms hold great promise for patients and are potentially disruptive in the oncology field. Looking forward to working with new and old colleagues
@EliotForster
#AlastairSmith

"a track record of building drug development teams in global companies."

lol Zoom. I often wonder why the most of these chartists are 'legends in their own minds.'

@Stifel reiterates its #BUY rating for Tissue_Regenix

after its FY results ??

??TP 0.9p
??BioRinse sales up 33%
?Capacity increased 50%

???"Rev growth accelerating, break-even expected during '22 and an EV/sales of 1.8x; we believe the shares are significantly undervalued"

Mr Cynic. FO you loser. It's not anyone's fault on here that you have come up short in life.
Seriously thinking of cancelling my L2 membership on LSE because of allowing bitter and twisted individuals from ruining informative discussion on LSE.

Thanks for the link Investor110 . I'd been topping up over the last few days and was beginning to wonder if I'd lost the plot.

Your link tells me all I need to know.

Sent Jupiter an email, informing them that I had used their services in the past, however because of their short position on Avacta, I would never be using or recommending their services ever again. In fact, I will actively discourage anyone form using their services.

Interesting company name check in the study. Would be very surprised if Merck are not following avct's progress closely.

"LS174T and HEK-293 cells were seeded in 24 well culture plates in DMEM at cell densities of
2.5 x 104 cells/well and incubated overnight for 18 h. Cells were then treated with 0 – 25 µg/ml of
CuAc (Merck, New Jersey, USA) dissolved in DMSO (Merck, New Jersey, USA) where the
maximum concentration of DMSO in the media was kept below 1%."

Personally hoping that Jupiter still have their shorts tightly in place around their nether regions, and that they get an almighty wedgie the equivalent of bungy jumping off a bridge with the elastic attached to their shorts.

I'm sure you'll find that they are all bitter and twisted individuals who've come up short in life.